Patient and disease characteristics
Characteristics . | Sibling . | VUD . | All . |
|---|---|---|---|
| Refractory anemia/refractory cytopenia (RA/RC) | 4 | 12 | 16 |
| Refractory anemia with excess blasts-I (RAEB-I) | 7 | 2 | 9 |
| Refractory anemia with excess blasts-II (RAEB-II) | 5 | 5 | 10 |
| Chronic myelomonocytic leukemia (CMML) | 1 | 3 | 4 |
| Acute myeloid leukemia with multilineage dysplasia (TLD-AML) | 7 | 16 | 23 |
| Total | 24 | 38 | 62 |
| IPSS | |||
| IPSS-Int1 | 6 | 9 | 15 |
| IPSS-Int2 | 5 | 10 | 15 |
| IPSS-high | 6 | 3 | 9 |
| AML | 7 | 16 | 23 |
| Cytogenetic risk1 | |||
| Good risk (normal karyotype, del(5q),-Y) | 11 | 16 | 27 |
| Intermediate risk (all other abnormalities) | 5 | 12 | 17 |
| Poor risk (complex [≥ 3 abnormalities], Chr 7 abnormalities) | 6 | 9 | 15 |
| Unknown | 2 | 1 | 3 |
| Comorbidities | |||
| Invasive pulmonary aspergillosis within 3 months of conditioning | 3 | 8 | 11 |
| Pulmonary transfer factor (diffusion capacity, TLco) less than 75% of predicted | 3 | 7 | 10 |
| Creatinine clearance, less than 75 mL/min | 2 | 1 | 3 |
| HLA antibody-mediated platelet refractoriness | 2 | 1 | 3 |
| Ulcerative colitis | 1 | 1 | 2 |
| Cardiomyopathy | 3 | 1 | 4 |
| Porphyria cutanea tarda | 0 | 1 | 1 |
| Fe overload | 0 | 3 | 3 |
| Epilepsy | 1 | 0 | 1 |
| Age alone | 8 | 16 | 24 |
Characteristics . | Sibling . | VUD . | All . |
|---|---|---|---|
| Refractory anemia/refractory cytopenia (RA/RC) | 4 | 12 | 16 |
| Refractory anemia with excess blasts-I (RAEB-I) | 7 | 2 | 9 |
| Refractory anemia with excess blasts-II (RAEB-II) | 5 | 5 | 10 |
| Chronic myelomonocytic leukemia (CMML) | 1 | 3 | 4 |
| Acute myeloid leukemia with multilineage dysplasia (TLD-AML) | 7 | 16 | 23 |
| Total | 24 | 38 | 62 |
| IPSS | |||
| IPSS-Int1 | 6 | 9 | 15 |
| IPSS-Int2 | 5 | 10 | 15 |
| IPSS-high | 6 | 3 | 9 |
| AML | 7 | 16 | 23 |
| Cytogenetic risk1 | |||
| Good risk (normal karyotype, del(5q),-Y) | 11 | 16 | 27 |
| Intermediate risk (all other abnormalities) | 5 | 12 | 17 |
| Poor risk (complex [≥ 3 abnormalities], Chr 7 abnormalities) | 6 | 9 | 15 |
| Unknown | 2 | 1 | 3 |
| Comorbidities | |||
| Invasive pulmonary aspergillosis within 3 months of conditioning | 3 | 8 | 11 |
| Pulmonary transfer factor (diffusion capacity, TLco) less than 75% of predicted | 3 | 7 | 10 |
| Creatinine clearance, less than 75 mL/min | 2 | 1 | 3 |
| HLA antibody-mediated platelet refractoriness | 2 | 1 | 3 |
| Ulcerative colitis | 1 | 1 | 2 |
| Cardiomyopathy | 3 | 1 | 4 |
| Porphyria cutanea tarda | 0 | 1 | 1 |
| Fe overload | 0 | 3 | 3 |
| Epilepsy | 1 | 0 | 1 |
| Age alone | 8 | 16 | 24 |